Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

4,150.00p
   
  • Change Today:
    -10.00p
  • 52 Week High: 4,500.00
  • 52 Week Low: 2,635.00
  • Currency: UK Pounds
  • Shares Issued: 5.21m
  • Volume: 2,005
  • Market Cap: £216.13m

Latest ShareCast News

Bioventix appoints Bruce Hiscox as chief financial officer

By Iain Gilbert

Date: Wednesday 01 Jul 2020

(Sharecast News) - Antibodies developer Bioventix named Bruce Hiscock would join the group its new chief financial officer on Wednesday.

Bioventix full-year revenue and profits improve

By Josh White

Date: Monday 21 Oct 2019

(Sharecast News) - Bioventix, which specialises in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, reported a 6% improvement in revenue for the year on Monday, to £9.3m.

Vitamin D antibodies drive first-half growth at Bioventix

By Josh White

Date: Friday 29 Mar 2019

(Sharecast News) - Monoclonal antibodies developer and supplier Bioventix reported a 24% improvement in its normalised revenue in its half-year report on Friday, to £4.4m.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 4,150.00p
Change Today -10.00p
% Change -0.24 %
52 Week High 4,500.00
52 Week Low 2,635.00
Volume 2,005
Shares Issued 5.21m
Market Cap £216.13m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
98.25% below the market average98.25% below the market average98.25% below the market average98.25% below the market average98.25% below the market average
89.09% below the sector average89.09% below the sector average89.09% below the sector average89.09% below the sector average89.09% below the sector average
Price Trend
84.12% above the market average84.12% above the market average84.12% above the market average84.12% above the market average84.12% above the market average
57.89% above the sector average57.89% above the sector average57.89% above the sector average57.89% above the sector average57.89% above the sector average
Income
76.49% below the market average76.49% below the market average76.49% below the market average76.49% below the market average76.49% below the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average
Growth
35.06% above the market average35.06% above the market average35.06% above the market average35.06% above the market average35.06% above the market average
8.57% above the sector average8.57% above the sector average8.57% above the sector average8.57% above the sector average8.57% above the sector average

Bioventix Dividends

  Latest Previous
  Interim Final
Ex-Div 09-Apr-20 31-Oct-19
Paid 28-Apr-20 15-Nov-19
Amount 36.00p 43.00p

Trades for 09-Jul-2020

Time Volume / Share Price
16:55 257 @ 4,123.97p
16:35 12 @ 4,150.00p
16:23 22 @ 4,144.00p
16:18 257 @ 4,150.00p
15:25 245 @ 4,100.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
Finance Director Treena Joan Turner
CFO Bruce Hiscock

Top of Page